Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)
Status:
Recruiting
Trial end date:
2025-01-25
Target enrollment:
Participant gender:
Summary
This is a Phase 2 trial that will test the efficacy and safety of crizanlizumab for the
treatment of retinal vasculopathy with cerebral leukoencephalopathy (RVCL), a very rare and
uniformly fatal genetic condition that affects the microvasculature, especially of the brain
and eye. There currently is no treatment for RVCL. A maximum of 20 patients will be enrolled.